Neuroone Medical Technologies (NMTC) Debt Ratio (2010 - 2024)

Neuroone Medical Technologies (NMTC) posted Debt Ratio of 0.02 for Q1 2024, up 41.7% on a QoQ basis from 0.02 in Q3 2023.

Neuroone Medical Technologies (NMTC) Debt Ratio (2010 - 2024) Analysis & Trends

Neuroone Medical Technologies' Debt Ratio history runs 9 years deep, the most recent figure standing at 0.02 for Q1 2024.

Quarterly Debt Ratio changed N/A year-over-year to 0.02 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was 0.02 (changed N/A YoY) and the FY2023 annual result came in at 0.02, changed N/A from the prior year.
Debt Ratio was 0.02 for Q1 2024 at Neuroone Medical Technologies, up from 0.02 in the prior quarter.
Across five years, Debt Ratio topped out at 0.02 in Q1 2024 and bottomed at 0.02 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	0.31
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	0.32
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	0.30
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	0.25
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	0.04
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	0.30
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	0.27
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	0.30
10	Neuroone Medical Technologies	7.99 Mn	5.19 Mn	990,264.00	-

Download Data